Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Discontinues Development Of Cholesterol Compound

This article was originally published in PharmAsia News

Executive Summary

Takeda halted development of an investigational drug, TAK-475 (lapaquistat), for the treatment of high cholesterol, based on efficacy and safety data, the company announced March 28.
Advertisement

Related Content

Japanese Takeda Buys Abbott’s Stake In TAP Joint U.S. Venture
Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market
Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data
Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data
Advertisement
UsernamePublicRestriction

Register

SC068039

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel